Effects on Fetal Development During Pregnancy
Methotrexate, a folate antagonist used for rheumatoid arthritis, cancer, and ectopic pregnancy, causes severe birth defects if taken during pregnancy. It inhibits dihydrofolate reductase, disrupting DNA synthesis and cell proliferation in rapidly dividing fetal tissues. Key risks include:
- Craniofacial dysmorphia (e.g., hypertelorism, micrognosis, limb defects like those in ADAM syndrome).
- Growth retardation and developmental delays.
- Embryotoxicity peaks in the first trimester, with 20-30% malformation rates reported in exposed pregnancies.[1][2]
The drug is absolutely contraindicated in pregnancy; women must use contraception for 3-6 months post-treatment, and men for 3 months due to sperm effects.[3]
Impact on Children with Juvenile Idiopathic Arthritis (JIA)
In children (typically 2+ years), low-dose weekly methotrexate (10-15 mg/m²) is standard first-line therapy for JIA. It reduces joint inflammation without halting linear growth or puberty in most cases:
- Long-term studies (up to 10 years) show no significant differences in height, weight, or bone age versus controls.
- Mild delays occur in <5% of cases, often linked to disease severity rather than the drug; growth rebounds after dose adjustment or remission.[4][5]
Monitoring includes annual bone density scans; calcium/vitamin D supplements mitigate rare osteopenia risks.
Cognitive and Neurological Development
No strong evidence links low-dose methotrexate to cognitive impairment in children. Neuropsychological tests in JIA patients on therapy for 2-5 years reveal:
- IQ and school performance comparable to peers.
- Rare reports of transient mood changes or headaches, resolving with dose reduction.
High-dose regimens (e.g., for leukemia) carry higher risks of leukoencephalopathy or neurotoxicity, but these use folinic acid rescue to protect.[6][7]
Long-Term Growth and Pubertal Effects
Puberty timing remains normal in 90%+ of treated children. A 20-year cohort study found:
- Final adult height within normal percentiles.
- Slight delays in very young starters (<5 years), but <2 cm loss on average.
Fertility is preserved; no increased infertility rates versus general population.[8]
Risks in Breastfeeding and Neonates
Methotrexate passes into breast milk at low levels (10-20% of maternal dose). It is not recommended during lactation due to potential infant bone marrow suppression and diarrhea. Pump-and-dump for 24-48 hours post-dose is advised if unavoidable.[9]
Sources
[1]: FDA Label - Methotrexate
[2]: Teratology Review - Methotrexate Embryopathy
[3]: ACOG Guidelines
[4]: Pediatric Rheumatology - Growth in Methotrexate-Treated JIA
[5]: Cochrane Review - Methotrexate for JIA
[6]: J Pediatrics - Cognitive Outcomes
[7]: Leukemia Journal - Neurotoxicity Review
[8]: Annals of Rheumatic Diseases - Long-Term Follow-Up
[9]: LactMed - Methotrexate